ロード中...
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than cytotoxic chemotherapy for metastatic lung non-squamous cell carcinoma harboring susceptible EGFR mutations when used a...
保存先:
| 出版年: | BMC Pharmacol Toxicol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5424380/ https://ncbi.nlm.nih.gov/pubmed/28486985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-017-0130-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|